Sesen Bio Inc. [NASDAQ: SESN] gained 1.53% or 0.06 points to close at $3.99 with a heavy trading volume of 4209767 shares. The company report on August 2, 2021 that Sesen Bio Strengthens Leadership Team as the Company Approaches the Potential Approval and Launch of Vicineum™.
Company announces hiring of Amy Ponpipom as Vice President, Assistant General Counsel.
Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, announced the expansion of its leadership team in support of the Company’s transformation into a commercial-stage company with the hiring of Amy Ponpipom as Vice President, Assistant General Counsel. The Company’s Biologics License Application (BLA) for Vicineum for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), the Company’s lead program, is currently under Priority Review with the US Food and Drug Administration (FDA) with a target Prescription Drug User Fee Act (PDUFA) date of August 18, 2021.
It opened the trading session at $3.93, the shares rose to $4.03 and dropped to $3.815, the range by which the price of stock traded the whole day. The daily chart for SESN points out that the company has recorded 120.44% gains over the past six months. However, it is still -338.46% lower than its most recent low trading price.
If we look at the average trading volume of 6.51M shares, SESN reached to a volume of 4209767 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Sesen Bio Inc. [SESN]:
H.C. Wainwright have made an estimate for Sesen Bio Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 11, 2019.
The Average True Range (ATR) for Sesen Bio Inc. is set at 0.26, with the Price to Sales ratio for SESN stock in the period of the last 12 months amounting to 44.85. The Price to Book ratio for the last quarter was 66.50, with the Price to Cash per share for the same quarter was set at 0.63.
Trading performance analysis for SESN stock
Sesen Bio Inc. [SESN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.91. With this latest performance, SESN shares dropped by -6.12% in over the last four-week period, additionally plugging by 120.44% over the last 6 months – not to mention a rise of 276.42% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SESN stock in for the last two-week period is set at 52.79, with the RSI for the last a single of trading hit 54.99, and the three-weeks RSI is set at 53.11 for Sesen Bio Inc. [SESN]. The present Moving Average for the last 50 days of trading for this stock 3.95, while it was recorded at 3.85 for the last single week of trading, and 2.51 for the last 200 days.
Sesen Bio Inc. [SESN]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Sesen Bio Inc. [SESN] shares currently have an operating margin of -287.09. Sesen Bio Inc.’s Net Margin is presently recorded at -199.33.
Reflecting on the efficiency of the workforce at the company, Sesen Bio Inc. [SESN] managed to generate an average of -$829,519 per employee.Sesen Bio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.30 and a Current Ratio set at 7.30.
An analysis of insider ownership at Sesen Bio Inc. [SESN]
There are presently around $162 million, or 24.80% of SESN stock, in the hands of institutional investors. The top three institutional holders of SESN stocks are: VANGUARD GROUP INC with ownership of 7,195,552, which is approximately 22.091% of the company’s market cap and around 0.03% of the total institutional ownership; TRV GP, LLC, holding 4,091,591 shares of the stock with an approximate value of $16.32 million in SESN stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $14.95 million in SESN stock with ownership of nearly 28.749% of the company’s market capitalization.
Positions in Sesen Bio Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 65 institutional holders increased their position in Sesen Bio Inc. [NASDAQ:SESN] by around 17,917,953 shares. Additionally, 15 investors decreased positions by around 5,013,301 shares, while 10 investors held positions by with 17,719,341 shares. The mentioned changes placed institutional holdings at 40,650,595 shares, according to the latest SEC report filing. SESN stock had 28 new institutional investments in for a total of 2,374,192 shares, while 5 institutional investors sold positions of 1,682,915 shares during the same period.